Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
SLNO Stock Chart & Stats
$48.38
-$1.55(-3.35%)
At close: 4:00 PM EST
$48.38
-$1.55(-3.35%)
Day’s Range― - ―
52-Week Range$41.50 - $90.32
Previous CloseN/A
Volume118.06K
Average Volume (3M)2.04M
Market Cap
$2.65B
Enterprise Value$3.27B
Total Cash (Recent Filing)$498.93M
Total Debt (Recent Filing)$2.81M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Mar 11, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.47
Shares Outstanding53,710,026
10 Day Avg. Volume1,434,800
30 Day Avg. Volume2,037,184
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)7.37
Price to Sales (P/S)0.00
P/FCF Ratio-26.05
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue33.10
Enterprise Value/Gross Profit33.73
Enterprise Value/Ebitda-49.26
Forecast
1Y Price Target
$115.00Price Target Upside137.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.19
Revenue Forecast (FY)$182.02M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSoleno achieved profitability during its first full quarter of launch with $26 million of positive net income for Q3.
Market ExpansionAccess continues to expand, with coverage policies now encompassing approximately 132 million lives across commercial, Medicare, and Medicaid channels.
Sales GrowthVykat XR Q3 sales of $66 million more than doubled from the $32.7 million reported in Q2, substantially exceeding consensus of $47 million and tracking with buyside expectations of $60 million+.
Bears Say
Clinical Trial ResultsData from the ongoing trial showed limited benefit on hyperphagia and mixed effects on body composition.
Launch DisruptionAn apparent disruption in the Vykat XR launch trajectory was observed following a short report published in August, contributing to a stagnation of PSFs and an uptick in discontinuations.
Market UncertaintyThere remains considerable uncertainty around commercialization plans in Europe, and the company has not yet committed to launching the drug independently abroad versus partnering with a larger pharma company.
Soleno Therapeutics News
SLNO FAQ
What was Soleno Therapeutics Inc’s price range in the past 12 months?
Soleno Therapeutics Inc lowest stock price was $41.50 and its highest was $90.32 in the past 12 months.
What is Soleno Therapeutics Inc’s market cap?
Soleno Therapeutics Inc’s market cap is $2.65B.
When is Soleno Therapeutics Inc’s upcoming earnings report date?
Soleno Therapeutics Inc’s upcoming earnings report date is Mar 11, 2026 which is in 82 days.
How were Soleno Therapeutics Inc’s earnings last quarter?
Soleno Therapeutics Inc released its earnings results on Nov 04, 2025. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.058 by $0.412.
Is Soleno Therapeutics Inc overvalued?
According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued.
Does Soleno Therapeutics Inc pay dividends?
Soleno Therapeutics Inc does not currently pay dividends.
What is Soleno Therapeutics Inc’s EPS estimate?
Soleno Therapeutics Inc’s EPS estimate is 0.62.
How many shares outstanding does Soleno Therapeutics Inc have?
Soleno Therapeutics Inc has 53,710,026 shares outstanding.
What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?
Soleno Therapeutics Inc reported an EPS of $0.47 in its last earnings report, beating expectations of $0.058. Following the earnings report the stock price went down -26.594%.
Which hedge fund is a major shareholder of Soleno Therapeutics Inc?
Currently, no hedge funds are holding shares in SLNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Soleno Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$115.00 (137.70% Upside)
$115.00 (137.70% Upside)
Blogger Sentiment
Bearish
SLNO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 785.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 12.4%
Last 30 Days ▼ 12.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.35%
12-Months-Change
Fundamentals
Return on Equity
-20.66%
Trailing 12-Months
Asset Growth
102.18%
Trailing 12-Months
Company Description
Soleno Therapeutics Inc
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
SLNO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented significant positive developments, including strong revenue growth, profitability, and broad payer coverage for VYKAT XR. However, these were tempered by challenges such as increased discontinuation rates and the impact of a short seller report affecting market momentum.View all SLNO earnings summariesSLNO Stock 12 Month Forecast
Average Price Target
$115.00
▲(137.70% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---